Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) kicked off on Friday, down -8.95% from the previous trading day, before settling in for the closing price of $1.28. Over the past 52 weeks, ZNTL has traded in a range of $1.21-$16.21.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -7.50%. With a float of $54.00 million, this company’s outstanding shares have now reached $71.28 million.
In an organization with 166 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 99.03%, operating margin of -283.57%, and the pretax margin is -245.74%.
Zentalis Pharmaceuticals Inc (ZNTL) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Zentalis Pharmaceuticals Inc is 24.81%, while institutional ownership is 86.96%. The most recent insider transaction that took place on Feb 06 ’25, was worth 45,656. In this transaction Chief Medical Officer of this company bought 20,000 shares at a rate of $2.28, taking the stock ownership to the 36,629 shares. Before that another transaction happened on Feb 11 ’25, when Company’s Former Director proposed sale 687 for $2.00, making the entire transaction worth $1,374.
Zentalis Pharmaceuticals Inc (ZNTL) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.62 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.50% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 6.08% during the next five years compared to -12.89% drop over the previous five years of trading.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Take a look at Zentalis Pharmaceuticals Inc’s (ZNTL) current performance indicators. Last quarter, stock had a quick ratio of 7.32. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.33, a number that is poised to hit -0.67 in the next quarter and is forecasted to reach -2.37 in one year’s time.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
Let’s dig in a bit further. During the last 5-days, its volume was 0.92 million. That was inferior than the volume of 1.72 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 5.35%. Additionally, its Average True Range was 0.17.
During the past 100 days, Zentalis Pharmaceuticals Inc’s (ZNTL) raw stochastic average was set at 1.21%, which indicates a significant decrease from 4.52% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 88.74% in the past 14 days, which was lower than the 107.16% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.9439, while its 200-day Moving Average is $3.0615. However, in the short run, Zentalis Pharmaceuticals Inc’s stock first resistance to watch stands at $1.2567. Second resistance stands at $1.3433. The third major resistance level sits at $1.4067. If the price goes on to break the first support level at $1.1067, it is likely to go to the next support level at $1.0433. Assuming the price breaks the second support level, the third support level stands at $0.9567.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Key Stats
The company with the Market Capitalisation of 84.02 million has total of 71,812K Shares Outstanding. Its annual sales at the moment are 67,430 K in contrast with the sum of -165,840 K annual income. Company’s last quarter sales were recorded 26,870 K and last quarter income was -47,470 K.
